PubMed

Clustering context-specific gene regulatory networks.

Ramesh A, Trevino R, VON Hoff DD, Kim S.

Pac Symp Biocomput. 2010:444-55.PMID: 19908396 [PubMed - in process]Related articlesFree article

Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.

Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD.

Clin Cancer Res. 2009 Nov 1;15(21):6519-28. Epub 2009 Oct 27.PMID: 19861455 [PubMed - in process]Related articles

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2.PMID: 19726763 [PubMed - indexed for MEDLINE]Related articles

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1173-8. Epub 2009 Sep 2.PMID: 19726761 [PubMed - indexed for MEDLINE]Related articles

Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies.

Mahadevan D, Dreisbach L, Kristedja T, Williams D, Obregon Y, Kurtin S, Von Hoff DD.

Am J Clin Oncol. 2009 Jul 10. [Epub ahead of print]PMID: 19593083 [PubMed - as supplied by publisher]Related articles

Pancreatic cancer--could it be that simple? A different context of vulnerability.

Von Hoff DD, Korn R, Mousses S.

Cancer Cell. 2009 Jul 7;16(1):7-8.PMID: 19573807 [PubMed - indexed for MEDLINE]Related articles

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43.PMID: 19519883 [PubMed - indexed for MEDLINE]Related articlesFree article

Patient selection for phase II trials.

Sonpavde G, Galsky MD, Hutson TE, Von Hoff DD.

Am J Clin Oncol. 2009 Apr;32(2):216-9.PMID: 19346816 [PubMed - in process]Related articles

DNA minor groove binders: back in the groove.

Cai X, Gray PJ Jr, Von Hoff DD.

Cancer Treat Rev. 2009 Aug;35(5):437-50. Epub 2009 Mar 27. Review.PMID: 19328629 [PubMed - indexed for MEDLINE]Related articles

Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature.

Borad MJ, Saadati H, Lakshmipathy A, Campbell E, Hopper P, Jameson G, Von Hoff DD, Saif MW.

Yale J Biol Med. 2009 Mar;82(1):1-6. Review.PMID: 19325940 [PubMed - indexed for MEDLINE]Related articlesFree article

Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.

Wang H, Stephens B, Von Hoff DD, Han H.

Pancreas. 2009 Jul;38(5):551-7.PMID: 19276868 [PubMed - indexed for MEDLINE]Related articles

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.

Galsky MD, Zaks T, Hassani H, Vocila L, Sonpavde G, Hutson TE, Von Hoff DD.

Invest New Drugs. 2009 Mar 6. [Epub ahead of print]PMID: 19262991 [PubMed - as supplied by publisher]Related articles

The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation.

DiMaio MA, Mikhailov A, Rieder CL, Von Hoff DD, Palazzo RE.

Mol Cancer Ther. 2009 Mar;8(3):592-601. Epub 2009 Mar 3.PMID: 19258425 [PubMed - indexed for MEDLINE]Related articles

Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.

Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, Narayan ST, Shakalya K, Croce KD, Georgiev IG, Nagle RB, Garewal H, Von Hoff DD, Mahadevan D.

Cancer Res. 2009 Mar 1;69(5):1933-40. Epub 2009 Feb 24.PMID: 19244123 [PubMed - indexed for MEDLINE]Related articles

Simulation of large-scale rule-based models.

Colvin J, Monine MI, Faeder JR, Hlavacek WS, Von Hoff DD, Posner RG.

Bioinformatics. 2009 Apr 1;25(7):910-7. Epub 2009 Feb 11.PMID: 19213740 [PubMed - indexed for MEDLINE]Related articles

UA62784, a novel inhibitor of centromere protein E kinesin-like protein.

Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD.

Mol Cancer Ther. 2009 Jan;8(1):36-44.PMID: 19139111 [PubMed - indexed for MEDLINE]Related articles

Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.

Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-Ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R.

Cancer Biol Ther. 2008 Nov 21;7(11). [Epub ahead of print]PMID: 18836286 [PubMed - as supplied by publisher]Related articlesFree article

Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD.

Pancreas. 2008 Oct;37(3):e39-44.PMID: 18815537 [PubMed - indexed for MEDLINE]Related articlesFree article

Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.

Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H.

Mol Cancer Ther. 2008 Sep;7(9):3071-80. Epub 2008 Sep 2.PMID: 18765825 [PubMed - indexed for MEDLINE]Related articlesFree article

Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.

Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M.

Am J Clin Oncol. 2008 Apr;31(2):157-62.PMID: 18391600 [PubMed - indexed for MEDLINE]Related articles

Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.

Warner SL, Stephens BJ, Von Hoff DD.

Curr Oncol Rep. 2008 Mar;10(2):122-9. Review.PMID: 18377825 [PubMed - indexed for MEDLINE]Related articles

Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.

Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G.

Pancreas. 2008 Mar;36(2):178-86.PMID: 18376310 [PubMed - indexed for MEDLINE]Related articles

Adrenocortical carcinoma survival rates correlated to genomic copy number variants.

Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, Demeure MJ.

Mol Cancer Ther. 2008 Feb;7(2):425-31.PMID: 18281524 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR, Asmar L, von Hoff DD.

Clin Genitourin Cancer. 2007 Dec;5(7):457-9.PMID: 18272030 [PubMed - indexed for MEDLINE]Related articles

Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.

Stephens B, Han H, Hostetter G, Demeure MJ, Von Hoff DD.

Mol Cancer Ther. 2008 Jan;7(1):202-10. Epub 2008 Jan 9.PMID: 18187808 [PubMed - indexed for MEDLINE]Related articlesFree article

Does intraosseous equal intravenous? A pharmacokinetic study.

Von Hoff DD, Kuhn JG, Burris HA 3rd, Miller LJ.

Am J Emerg Med. 2008 Jan;26(1):31-8.PMID: 18082778 [PubMed - indexed for MEDLINE]Related articles

Identification of a novel inhibitor of urokinase-type plasminogen activator.

Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H.

Mol Cancer Ther. 2007 Apr;6(4):1348-56.PMID: 17431113 [PubMed - indexed for MEDLINE]Related articlesFree article

Tumor-stroma interactions in pancreatic ductal adenocarcinoma.

Mahadevan D, Von Hoff DD.

Mol Cancer Ther. 2007 Apr;6(4):1186-97. Epub 2007 Apr 3. Review.PMID: 17406031 [PubMed - indexed for MEDLINE]Related articlesFree article

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.

Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A.

Cancer Chemother Pharmacol. 2007 Jul;60(2):295-303. Epub 2006 Dec 6.PMID: 17149608 [PubMed - indexed for MEDLINE]Related articles

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.

Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.

Mol Cancer Ther. 2006 Nov;5(11):2613-23. Epub 2006 Nov 6.PMID: 17088436 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.

Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H.

Mol Cancer Ther. 2006 Oct;5(10):2450-8.PMID: 17041088 [PubMed - indexed for MEDLINE]Related articlesFree article

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

Wang H, Han H, Von Hoff DD.

Cancer Res. 2006 Oct 1;66(19):9722-30.PMID: 17018631 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD.

Clin Cancer Res. 2006 Sep 1;12(17):5182-9.PMID: 16951237 [PubMed - indexed for MEDLINE]Related articlesFree article

Aurora sheds light on head and neck squamous cell carcinoma.

Han H, Von Hoff DD.

Clin Cancer Res. 2006 Sep 1;12(17):5003-4. Review. No abstract available. PMID: 16951211 [PubMed - indexed for MEDLINE]Related articlesFree article

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.

Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH.

Mol Cancer Ther. 2006 Jul;5(7):1764-73. Erratum in: Mol Cancer Ther. 2006 Dec;5(12):3312. Mahadevan, Daruka [added]. PMID: 16891462 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):513-20. Review.PMID: 16890805 [PubMed - indexed for MEDLINE]Related articles

Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element.

Hurley LH, Von Hoff DD, Siddiqui-Jain A, Yang D.

Semin Oncol. 2006 Aug;33(4):498-512. Review.PMID: 16890804 [PubMed - indexed for MEDLINE]Related articles

Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.

Warner SL, Gray PJ, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):436-48. Review.PMID: 16890798 [PubMed - indexed for MEDLINE]Related articles

What's new in pancreatic cancer treatment pipeline?

Von Hoff DD.

Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):315-26. Review.PMID: 16549330 [PubMed - indexed for MEDLINE]Related articles

PRL phosphatases as potential molecular targets in cancer.

Stephens BJ, Han H, Gokhale V, Von Hoff DD.

Mol Cancer Ther. 2005 Nov;4(11):1653-61. Review.PMID: 16275986 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD.

J Clin Oncol. 2005 Nov 1;23(31):7785-93.PMID: 16258082 [PubMed - indexed for MEDLINE]Related articles

Telomerase and telomere inhibitors in preclinical development.

Sharma S, Raymond E, Soda H, Von Hoff DD.

Expert Opin Investig Drugs. 1997 Sep;6(9):1179-85.PMID: 15991892 [PubMed]Related articles

Complex and simple.

Lansky EP, Von Hoff DD.

Leuk Res. 2005 Jun;29(6):601-2. Epub 2005 Feb 26. No abstract available. PMID: 15863195 [PubMed - indexed for MEDLINE]Related articles

Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.

Manikumar G, Wadkins RM, Bearss D, Von Hoff DD, Wani MC, Wall ME.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5377-81.PMID: 15454230 [PubMed - indexed for MEDLINE]Related articles

Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.

Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, Von Hoff DD.

Cancer Res. 2004 Sep 15;64(18):6679-83.PMID: 15374984 [PubMed - indexed for MEDLINE]Related articlesFree article

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR; ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays.

J Clin Oncol. 2004 Sep 1;22(17):3631-8. Epub 2004 Aug 2.PMID: 15289488 [PubMed - indexed for MEDLINE]Related articles

Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.

Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, Von Hoff DD.

Curr Med Chem Anticancer Agents. 2004 Jul;4(4):327-34.PMID: 15281905 [PubMed - indexed for MEDLINE]Related articles

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD.

Mol Cancer Ther. 2004 May;3(5):641-6.PMID: 15141022 [PubMed - indexed for MEDLINE]Related articlesFree article

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ.

Mol Cancer Ther. 2004 Apr;3(4):451-7.PMID: 15078988 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.

Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2004 Mar 1;10(5):1645-56.PMID: 15014015 [PubMed - indexed for MEDLINE]Related articlesFree article